The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human phase I study of the antiangiogenic vaccine (OTS11101) targeting VEGFR-1 in patients with solid tumors.
H. Hayashi
No relevant relationships to disclose
T. Kurata
No relevant relationships to disclose
Y. Fujisaka
No relevant relationships to disclose
T. Satoh
No relevant relationships to disclose
M. Takeda
No relevant relationships to disclose
M. Miyazaki
No relevant relationships to disclose
T. Okabe
No relevant relationships to disclose
H. Kiyota
No relevant relationships to disclose
K. Tanaka
No relevant relationships to disclose
T. Tsunoda
Employment or Leadership Position - OncoTherapy Science
K. Nakagawa
No relevant relationships to disclose